Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
Earnings Data
Report Date
Mar 19, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.42Last Year’s EPS
0.48Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlighted significant revenue growth and strategic initiatives like the 'Get Nephi On Us' program and global expansion. However, challenges such as temporary pauses in market share growth, data inaccuracies, and expected Q4 sales decline were noted.Company Guidance
Significant Revenue Growth
U.S. net product revenue for Nephi reached $31.3 million in Q3, representing a 2.5-fold increase from the prior quarter and exceeding consensus expectations of $28.3 million.
Global Expansion and Approvals
Nephi received approval in Japan with launch anticipated in 2025, expected approvals in Canada and China by 2026.
Positive Market Feedback and Real-World Data
Real-world data shows Nephi effectively treats anaphylaxis with a single dose in nine out of ten patients, aligning with epinephrine injections.
Launch of 'Get Nephi On Us' Program
Introduced a program to simplify access to Nephi with virtual prescriber interactions at no cost, anticipated to accelerate sales.
Strong Cash Position
Ended Q3 with $288 million in cash, cash equivalents, and short-term investments, supported by a $250 million term loan facility.
SPRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SPRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $8.85 | $8.88 | +0.34% |
Aug 13, 2025 | $16.66 | $15.82 | -5.04% |
May 14, 2025 | $13.35 | $12.10 | -9.36% |
Mar 20, 2025 | $11.65 | $14.31 | +22.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ARS Pharmaceuticals (SPRY) report earnings?
ARS Pharmaceuticals (SPRY) is schdueled to report earning on Mar 19, 2026, After Close (Confirmed).
What is ARS Pharmaceuticals (SPRY) earnings time?
ARS Pharmaceuticals (SPRY) earnings time is at Mar 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SPRY EPS forecast?
SPRY EPS forecast for the fiscal quarter 2025 (Q4) is -0.42.